Caryn Peterson

In 2010, Ms. Peterson joined Moerae Matrix, Inc. as Vice President of Regulatory Affairs to oversee development of the Company’s drug portfolio from IND-enabling studies into the clinic. Ms. Peterson has over 30 years of pharmaceutical industry experience, including research and development, regulatory affairs, and operations. She has extensive experience in the area of global regulatory affairs for small molecules, peptide therapeutics, and biologics. Ms. Peterson co-founded the consulting firm DSC Associates (“DSC”) in 2004, to provide consulting services to the pharmaceutical, biotechnology and medical device industries, focusing on preclinical, regulatory and clinical strategies designed to streamline product development. Prior to founding DSC, she served on FeRx Incorporated’s Executive Management Team as Vice President of Regulatory Affairs responsible for development and subsequent execution of the global nonclinical, clinical and regulatory strategies for the lead compound and platform technology. Prior to FeRx, Ms. Peterson held senior managerial positions at Amylin Pharmaceuticals in Pharmaceutical Development and Regulatory Affairs. Ms. Peterson was involved in the early discovery program and subsequent clinical development of pramlintide (Symlin®), a peptide drug for Type 1 diabetes.